Otsuka America Pharmaceutical
在场
Otsuka America Pharmaceutical 的所有者是 Otsuka Holdings.
是其中之一......
Otsuka Holdings 是一家在股票代码 4578 (JP) 下上市的公司。
Otsuka Holdings 在 10 个国家有直接业务。Otsuka Holdings 拥有 25家子公司，其中包括 Astex、Astex Pharmaceuticals 和 Cambridge Isotope Laboratories。
他们在：
高管
查看带有其 25 名主要高管的组织结构图
Otsuka America Pharmaceutical 搜索最多的简介
- Tarek Rabah, President and Chief Executive Officer
- Nick Kurahashi, Executive Vice President, Global Pharmaceutical St...
- Steve Rosen, Vice President and Chief Financial Officer
创建提醒
跟踪 Otsuka America Pharmaceutical 的高管变动
药店
Otsuka Holdings 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Otsuka America Pharmaceutical 的最新新闻稿
- Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease | Otsuka US
- FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults | Otsuka US
- Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder | Otsuka US
- Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer’s Dementia | Otsuka US
- Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder | Otsuka
- Otsuka and Verily Expand Collaboration on Novel Clinical Trials Solutions to Accelerate Research in Major Depressive Disorder | Otsuka US
- Otsuka and Lundbeck announce FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia | Otsuka US
- Otsuka Pharmaceutical and Lundbeck Present Positive Data From Multiple Phase 3 Studies Showing Brexpiprazole Significantly Improved Symptoms of Agitation in Patients with Alzheimer's Dementia at the 2022 Clinical Trials for Alzheimer’s Disease Congress |
- Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder | Otsuka US
- Avanir Pharmaceuticals, Inc. Business Will Be Integrated Into Otsuka America Pharmaceutical, Inc. as of January 1, 2023 | Otsuka US
- View more press releases Close
通过电子邮件
